Simplify Propel Opportunities ETF Rating $17.70 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Simplify Propel Opportunities ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.SURI Aggregate RatingModerate Buy 2.55Holdings in SURI have an aggregate rating of Moderate Buy based on 188 analyst ratings issued in the past year covering 23 companies (95.3% of the portfolio).SURI Aggregate Price Target$17.70High Prediction$17.70Average Prediction$17.70Low Prediction$17.70Holdings in SURI have an aggregate price target of $17.70 and a range of $17.70 to $17.70 covering 23 companies (95.3% of the portfolio).SURI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy13 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Simplify Propel Opportunities ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 SURI Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings43.45%PAGPPlains GP$25.952.2538 of 5 stars2.33$22.50 -13.3%12Dividend Announcement8.84%ACHVAchieve Life Sciences$4.692.2634 of 5 stars3.00$14.67 212.7%6Gap Up6.21%MISTMilestone Pharmaceuticals$1.412.5397 of 5 stars2.50$7.25 414.2%6Gap Up3.79%DCTHDelcath Systems$11.022.3328 of 5 stars2.43$22.50 104.2%7Gap Up3.72%PHATPhathom Pharmaceuticals$11.332.4741 of 5 stars2.88$25.00 120.7%83.58%ABEOAbeona Therapeutics$5.442.4095 of 5 stars2.33$19.00 249.3%3Gap Up2.99%CORTCorcept Therapeutics$60.223.8452 of 5 stars2.75$70.83 17.6%8Analyst Revision2.59%OCSOculis$29.493.2553 of 5 stars2.89$49.38 67.4%92.39%CLDXCelldex Therapeutics$30.732.19 of 5 stars2.80$49.78 62.0%102.03%LONAAthira Pharma$10.331.5606 of 5 stars2.25$10.00 -3.2%42.00%CMPSCompass Pathways$11.813.6548 of 5 stars2.93$20.58 74.3%141.65%PALIPalisade Bio$1.952.299 of 5 stars2.88$10.20 423.1%8Gap Up1.52%IVAInventiva$5.072.5093 of 5 stars3.10$16.56 226.5%10Gap Up1.51%AQSTAquestive Therapeutics$4.122.3183 of 5 stars3.00$8.80 113.6%8Gap Up1.49%KYTXKyverna Therapeutics$8.672.4178 of 5 stars2.67$30.00 246.0%6Gap Up1.27%ZVRAZevra Therapeutics$10.033.5146 of 5 stars2.78$23.33 132.6%91.17%OBIOOrchestra BioMed$4.064.2927 of 5 stars2.57$13.60 235.0%7Positive News1.05%ARTVArtiva Biotherapeutics$7.873.8048 of 5 stars2.83$39.00 395.6%60.96%SABSSAB Biotherapeutics$3.903.9312 of 5 stars2.80$11.00 182.1%100.88%OCULOcular Therapeutix$8.232.3173 of 5 stars2.79$23.78 188.9%140.77%EYPTEyepoint Pharmaceuticals$12.932.3815 of 5 stars3.00$31.80 145.9%70.75%IMUXImmunic$13.053.7975 of 5 stars3.00$47.57 264.5%11Gap Down0.68%UPBUpstream Bio$8.372.1246 of 5 stars2.40$38.75 363.0%5Gap Down This page (NYSEARCA:SURI) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Simplify Propel Opportunities ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Simplify Propel Opportunities ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
